Introduction：Basic information about CAS 53882-12-5|Lodoxamide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lodoxamide |
|---|
| CAS Number | 53882-12-5 | Molecular Weight | 311.63500 |
|---|
| Density | 1.78g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C11H6ClN3O6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid |
|---|
| Synonym | More Synonyms |
|---|
Lodoxamide BiologicalActivity
| Description | Lodoxamide is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Histamine ReceptorSignaling Pathways >>Immunology/Inflammation >>Histamine ReceptorResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | Lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells[1]. The chemotactic response of eosinophils to fMLP as well as to IL-5 is significant and dose-dependent inhibited by Lodoxamide. Lodoxamide is also able to strongly inhibit the release of eosinophil peroxidase after IgA-dependent activation and, to a lesser extent, the release of eosinophil cationic protein and eosinophil-derived neurotoxin[2]. |
|---|
| In Vivo | Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys[1]. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance[3]. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep[4]. |
|---|
| References | [1]. Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94. [2]. Capron M,et al. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol. 1998 Jun;116(2):140-6. [3]. Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7. [4]. Mann JS, et al. Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 1985 Jul;76(1):83-90. |
|---|
Chemical & Physical Properties
| Density | 1.78g/cm3 |
|---|
| Molecular Formula | C11H6ClN3O6 |
|---|
| Molecular Weight | 311.63500 |
|---|
| Exact Mass | 310.99500 |
|---|
| PSA | 156.59000 |
|---|
| LogP | 0.40388 |
|---|
| Index of Refraction | 1.673 |
|---|
| Storage condition | 2-8℃ |
|---|
Safety Information
Customs
| HS Code | 2926909090 |
|---|
| Summary | HS:2926909090 other nitrile-function compounds VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
|---|
Synonyms
| UNII-SPU695OD73 |
| Acetic acid,2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxo |
| Lodoxamidum [INN-Latin] |
| N,N'-(2-Chlor-5-cyan-m-phenylen)-dioxamsaeure |
| Alomide (TN) |
| Lodoxamidum |
| Lodoxamida [INN-Spanish] |
| N,N'-(2-Chlor-5-cyan-3-phenylen)dioxamsaeure |
| N-N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid |
| Lodoxamida |
| diesters of N,N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid |
| Lodoxamide |
